SCHEMBL7425804

SCHEMBL7425804

Clc1ccsc1-c1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.53
RAB9A P51151 6/20 0.53
NPC1 O15118 5/20 0.53
TDP1 Q9NUW8 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAPT P10636 5/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 4/20 0.48
CCR1 P32246 3/20 0.48
CCR5 P51681 3/20 0.48
CCR8 P51685 3/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
METAP1 P53582 1/20 0.48
BLM P54132 1/20 0.48
HIF1A Q16665 1/20 0.48
DOHH Q9BU89 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6745096 0.78 KDM4E (0.50) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL5849391 0.78 MAPT (0.46) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL4552315 0.77 SMN1; SMN2 (0.61) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL4974076 0.77 KDM4E (0.48) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL18752563 0.77 ALDH1A1 (0.50) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL3714318 0.77 KDM4E (0.48) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL28931079 0.77 KDM4E (0.48) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL28554182 0.74 KDM4E (0.49) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL6754739 0.73 KDM4E (0.48) KDM4ERAB9ANPC1TDP1SMN1; SMN2
SCHEMBL5795256 0.73 TRPM8 (0.44) KDM4ERAB9ANPC1TDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1152049-C Treatment of insulin resistance with growth hormone secretagogues �Ʒ� 2004-06-02 CN disclosed
CN-1418882-A Substituted sulfonic acid N- [ (aminoiminomethyl) phenylalkyl ] -azacyclic amide compounds AVENTIS PHARMACENEITCALS INC (US) 2003-05-21 CN disclosed
CN-1093856-C Substituted sulfonic acid N- [ (aminoiminomethyl) phenylalkyl ] -azacyclic amide compounds AVENTIS PHARM PROD INC (US) 2002-11-06 CN disclosed
EP-0894088-A4 SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS RHONE POULENC RORER PHARMA (US) 2001-12-05 EP disclosed
US-6124264-A GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS PFIZER INC. (US) 2000-09-26 US disclosed
US-6110932-A INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING PFIZER INC. (US) 2000-08-29 US disclosed
US-6107306-A OSTEOPOROSIS PFIZER INC. (US) 2000-08-22 US disclosed
US-6034093-A Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 2000-03-07 US disclosed
CN-1213370-A Substituted sulfonic acid N- [ (aminoiminomethyl) phenylalkyl ] -azacyclic amide compounds RHONE POULENC RORER PHAMACEUTI (US) 1999-04-07 CN disclosed
EP-0894088-A1 SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-02-03 EP disclosed
WO-1998024784-A1 SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-06-11 WO disclosed
US-5731315-A Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-03-24 US disclosed